The Medical School of Milan of the Ambrosiana University, with the Patronage of the Italian National Health Committee, organized the   specialization course,  dedicated to family and public health physicians  on the theme:

“Prevention and person-centered treatment of COVID-19 by variants of SARS-COV 2 and communicable diseases”

The course is the first edition in Italian of a European and international teaching program on the prevention of COVID-19, inspired by the Person-Centered Medicine application in theory and Medical Education, of which the Medical School of Milan of the Ambrosiana University is a pioneer and recognized world leader by the WHO. The course is aimed at teaching the correct epistemological and scientific paradigm to cope with the SARS-VOC 2 pandemic, based on the new antiviral allostasis and preventive immunostimulation paradigm, before a mass vaccination with genotoxic mRNA and vectorial vaccines also administered to children, adolescents and young people, not at risk of serious infections, if healthy. These mRNA and vector vaccines, inducers of an epigenetic earthquake, would have required years of experimentation to study even fatal adverse effects with serious damage to the health of the world population. The Course is coordinated by prof. Giuseppe R.Brera, currently the world’s leading expert on the prevention of COVID-19- wrote the only existing treatise on the subject and is the author of the theoretical paradigm of Person-Centered Medicine- is given by Maria Rita Gismondo, (Milan State University) virologist of international fame, Maurizio Federico, ( Director in the Italian Health Institute of the World Center of Global Health) who has in testing a pan-vaccine against the COVID-19, Salvatore Chirumbolo (University of Verona)  and Sergio Pandolfi  (University of Pavia) the most important Italian scholars on the early therapy of COVID-19, and the clinical “heresy” of the former Italian Health Minister’s, Roberto Speranza, illiterate paradigm” Paracetamol and vigilant wait” that cost thousands of deaths and hospital admissions. Medical Education is coordinated by prof. Vito Galante of the Milan School of Medicine with the quality procedure of the Ambrosiana University.

PROGRAM (1st edition-Italian)

Information to subscribe the European and International edition


J Mazetes -Managing editor

Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer


William Wang , David C. Kaelber; Rong Xu, et al in an article on JAMA  oncology on April 8,  have irrefutably highlighted that the mRNA vaccination anti COVID increases the rate of infection, hospitalization, and mortality in cancer patients.
The research, a retrospective cohort study on 2020-2021 vaccinated cancer patients,  in the USA, comparing 45 253 vaccinated cancer patients, with 12 common neoplastic diseases including hematological ones, with healthy vaccinated (total sample of vaccinated with two doses of Pfizer or Moderna n=636.435), showed a significant increase in infections, hospitalizations, and mortality in neoplastic patients.

“Among 45 253 vaccinated patients with cancer (mean [SD] age, 68.7 [12.4] years), 53.5% were female, 3.8% were Asian individuals, 15.4% were Black individuals, 4.9% were Hispanic individuals, and 74.1% were White individuals. Breakthrough SARS-CoV-2 infections in patients with cancer increased from December 2020 to November 2021 and reached 52.1 new cases per 1000 persons in November 2021. The cumulative risk of breakthrough infections in patients with all cancer was 13.6%, with the highest risk for pancreatic (24.7%), liver (22.8%), lung (20.4%), and colorectal (17.5%) cancers, and the lowest risk for thyroid (10.3%), endometrial (11.9%), and breast (11.9%) cancers, vs 4.9% in the noncancer population (P < .001). Patients with cancer had significantly increased risk for breakthrough infections vs patients without cancer (HR, 1.24; 95% CI, 1.19-1.29), with greatest risk for liver (HR, 1.78; 95% CI, 1.38-2.29), lung (HR, 1.73; 95% CI, 1.50-1.99), pancreatic (HR, 1.64; 95% CI, 1.24-2.18), and colorectal (HR, 1.53; 95% CI, 1.32-1.77) cancers and lowest risk for thyroid (HR, 1.07; 95% CI, 0.88-1.30) and skin (HR, 1.17; 95% CI, 0.99-1.38) cancers. Patients who had medical encounters for cancer within the past year had higher risk for breakthrough infections than those who did not (HR, 1.24; 95% CI, 1.18-1.31). Among patients with cancer, the overall risk for hospitalizations and mortality was 31.6% and 3.9%, respectively, in patients with breakthrough infections, vs 6.7% and 1.3% in those without breakthrough infections (HR for hospitalization: 13.48; 95% CI, 11.42-15.91; HR for mortality: 6.76; 95% CI, 4.97-9.20)”

The significant increase in infections, hospitalization and mortality in vaccinated cancer patients could be explained in a multifactorial way by the decrease in the immune capabilities of cancer patients due to chemotherapy and the inhibition of immunity made by mRNA vaccines due to the silencing of tumor suppressor genes ( P 53), by the inactivation of microRNAs and by the inhibition of MHC2 necessary for the activation of cellular immunity (e.g. cytotoxic lymphocytes).
The inhibition of immunity is therefore proportional to the number of doses of mRNA vaccines, and immunosenescence and is also caused by atherosclerotic comorbidities. mRNA vaccines expose the population to greater vulnerability to cancer, and infections as highlighted by prof. Giuseppe R. Brera, in his work on the genotoxicity of mRNA vaccines and in his treatise that introduced the antiviral Allostasis and the preventive Immunostimulation to prevent infections by variants of SARS-COV 2.

The only possibility for cancer patients and the population to prevent infections by variants of SARS-COV 2 and increase defenses against neoplasms is antiviral allostasis and preventive immunostimulation also active against all communicable diseases and cancer.


JM  WHC Editorial Manager

Translate »